United States · FDA National Drug Code directory
FLUZONE TIV SH 2026
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 49281-315_5b401352-1683-4309-9708-b20472557a44
- Product NDC
- 49281-315
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/SINGAPORE/GP20238/2024 IVR-277 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), and INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED)
- Labeler
- Sanofi Vaccines US Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20260220 / 20261231
Source-listed ingredients
- INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mL
- INFLUENZA A VIRUS A/SINGAPORE/GP20238/2024 IVR-277 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mL
- INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, MULTI-DOSE in 1 PACKAGE (49281-315-15) / 5 mL in 1 VIAL, MULTI-DOSE (49281-315-78) · 49281-315-15
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →